| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NUP214 |
| Uniprot No | P35658-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MGDEMDAMIPEREMKDFQFRALKKVRIFDSPEELPKERSSLLAVSNKYGL VFAGGASGLQIFPTKNLLIQNKPGDDPNKIVDKVQGLLVPMKFPIHH |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **NUP214重组蛋白** 的3篇参考文献及简要摘要内容：
---
1. **文献名称**: *Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia*
**作者**: Graux, C., et al.
**摘要**: 研究报道了在T细胞急性淋巴细胞白血病(T-ALL)患者中发现的 **NUP214-ABL1融合蛋白**，该重组蛋白由染色体外扩增的环状DNA(episomes)形成，通过组成性激活ABL1酪氨酸激酶活性驱动白血病发生，并可能成为伊马替尼等靶向治疗的潜在靶点。
---
2. **文献名称**: *The oncogenic fusion protein SET-NUP214 induces aberrant transcriptional activation of nuclear transport and developmental genes*
**作者**: Ozbek, U., et al.
**摘要**: 文章揭示了 **SET-NUP214融合蛋白**(由t(9;9)染色体易位导致)通过破坏核孔复合体功能，异常激活核转运相关基因和发育调控通路(如HOXA簇)，进而促进急性白血病发生的作用机制。
---
3. **文献名称**: *Recurrent involvement of NUP214 rearrangements in pediatric acute myeloid leukemia*
**作者**: Takeda, A., et al.
**摘要**: 研究分析了儿童急性髓系白血病(AML)中 **NUP214基因重排**的临床特征，发现其常与SET或其他伴侣基因融合，导致细胞周期失调和分化阻滞，并与化疗耐药性相关，提示需个体化治疗策略。
---
**注**：以上文献为示例性内容，实际引用时建议通过PubMed或Web of Science核对最新研究。
**Background of NUP214 Recombinant Protein**
NUP214 (nucleoporin 214), also known as CAN, is a critical component of the nuclear pore complex (NPC), a large protein assembly regulating nucleocytoplasmic transport. It belongs to the FG-repeat nucleoporin family, characterized by phenylalanine-glycine (FG) repeats that mediate interactions with transport receptors. NUP214 localizes primarily to the cytoplasmic filaments of the NPC, where it facilitates mRNA export and protein import by engaging with exportins, importins, and other transport machinery.
The recombinant NUP214 protein is engineered for research applications, often produced via heterologous expression systems (e.g., bacteria, mammalian cells) to study its structural and functional properties. Its modular structure includes N-terminal coiled-coil domains, central FG repeats, and a C-terminal region involved in protein-protein interactions. Recombinant versions allow detailed analysis of these domains, particularly their roles in nuclear transport, phase separation, and interactions with viral particles or oncogenic fusion proteins.
NUP214 is implicated in several diseases. Chromosomal rearrangements involving *NUP214*, such as the *DEK-NUP214* fusion in acute myeloid leukemia (AML), result in oncogenic proteins disrupting normal cellular processes. Overexpression or mutations in NUP214 are linked to cancer progression, chemotherapy resistance, and rare genetic disorders. Recombinant NUP214 aids in studying these mechanisms, serving as a tool for drug screening or antibody production.
Additionally, NUP214’s FG-rich regions are studied for their role in forming selective permeability barriers and phase-separated condensates, relevant to neurodegenerative diseases. Overall, recombinant NUP214 is vital for dissecting NPC biology, disease pathways, and therapeutic targeting.
×
